Vyome Holdings (HIND) Return on Capital Employed (2016 - 2026)
Vyome Holdings (HIND) posted quarterly Return on Capital Employed of 223.03% for Q1 2026, down 32595.0% year-over-year from N/an in Q1 2025, and up 30.17% quarter-over-quarter from 319.38% in Q4 2025.
Vyome Holdings (HIND) Return on Capital Employed (2016 - 2026) Analysis & Trends
Vyome Holdings' Return on Capital Employed history runs 11 years deep, the most recent figure standing at 223.03% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 32595.0% year-over-year to 223.03%; the TTM figure through Mar 2026 stood at 223.03% (down 32595.0% YoY), while the FY2025 annual figure was 868.0%, down 51180.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 223.03%, up from 319.38% in the prior quarter.
- The five-year high for Return on Capital Employed was 3401.07% in Q3 2024, with the low at 713.9% in Q1 2023.
- The 5-year median for Return on Capital Employed is 239.76% (2025), against an average of 45.39%.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed soared 396303 bps in 2024, then slumped 364083 bps in 2025.
- Vyome Holdings' Return on Capital Employed stood at 409.01% in 2022, then soared by 31 bps to 281.31% in 2023, then jumped by 139 bps to 108.87% in 2024, then plunged by 393 bps to 319.38% in 2025, then jumped by 30 bps to 223.03% in 2026.
- Business Quant data shows HIND's Return on Capital Employed at 223.03% in Q1 2026, 319.38% in Q4 2025, and 239.76% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 26.09% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -50.93% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 7.88% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -6.85% |
| 10 | Vyome Holdings | 16.00 Mn | 8.11 Mn | 11,658.00 | -152.53% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -152.53% |
| Mar 31, 2026 | -223.03% |
| Dec 31, 2025 | -319.38% |
| Sep 30, 2025 | -239.76% |
| Jun 30, 2025 | -171.76% |
| Mar 31, 2025 | 102.93% |
| Dec 31, 2024 | 108.87% |
| Sep 30, 2024 | 3,401.07% |
| Jun 30, 2024 | -244.20% |
| Mar 31, 2024 | -201.77% |
| Dec 31, 2023 | -281.31% |
| Sep 30, 2023 | -561.96% |
| Jun 30, 2023 | -398.03% |
| Mar 31, 2023 | -713.90% |
| Dec 31, 2022 | -409.01% |
| Sep 30, 2022 | -259.47% |
| Jun 30, 2022 | -205.12% |
| Mar 31, 2022 | -155.81% |
| Dec 31, 2021 | -90.26% |
| Sep 30, 2021 | -24.79% |